Clinical Trials Browser

Phase 1/2 × Terminated × mavorixafor × Clear all

NCT02923531 2022-12-29

Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma

Phase 1/2 Terminated

9 enrolled 10 charts

Carcinoma, Renal Cell